Eline G M van Geffen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eline G M van Geffen has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
- Pieter Job Tanis
Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
4 shared publications A K Talsma
2 shared publicationsDutch Snapshot Research Group
2 shared publicationsG L Beets
2 shared publicationsJ B Tuynman
2 shared publicationsJ W A Leijtens
2 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (4)
Oncological outcomes and treatment characteristics of patients with cT3-4 mesorectal fascia positive rectal cancer operated in 2016: Dutch nationwide cohort with standardized magnetic resonance imaging re-assessment
Background: Rectal cancer with mesorectal fascia involvement (MRF+) requires neoadjuvant downstaging and/or induction therapy, followed by (beyond) total mesorectal excision and/or multivisceral resection (MVR) depending on response. Decisions on the need for MVR and plane of dissection vary. This nationwide cross-sectional study aimed to evaluate treatment and oncological outcomes in MRF+ primary rectal cancer and the impact of MVR types. Methods: Using collaborative research, extensive clinical data on all rectal cancer resections in 2016 across 67 Dutch hospitals were retrospectively collected. Patients with cT3-4 MRF+ primary rectal cancer and standardized re-assessment of primary and restaging magnetic resonance imaging were selected. Patients were categorized by radiologically involved structures or organs and by MVR type. The primary outcome measures were microscopically positive margin (R1) resection rate, 4-year cumulative local recurrence, and 4-year overall survival. Results: Of 3178 patients registered, 571 cT3-4 MRF+ were selected resections, 125 of which were MVR. Tumours remained MRF+ on restaging magnetic resonance imaging in 76.4%. The overall R1 rate was 11.8% (9.7% in cT3/4a MRF+ and 17.9% in cT4b tumours). The R1 rate after MVR was 20.8%. Overall, the 4-year local recurrence rate was 15.1% and 4-year overall survival 67.5%. When comparing total mesorectal excision with MVR and/or beyond total mesorectal excision, the local recurrence rate was 12.7% versus 24.2% (P = 0.001), and overall survival 71.3% versus 53.7% (P < 0.001). Patients with radiological anterior involvement seemed to have a higher R1 rate compared with other locations. Anterior resections in both men and women appeared to be associated with relatively low local recurrence and high overall survival, whereas other resections resulted in numerically lower R1 rates, but worse long-term oncological outcomes. However, neither anatomical location of MRF+ and/or ingrowth nor MVR type was significantly associated with the primary outcomes. Pelvic sepsis (hazard ratio 1.533, 95% confidence interval 1.0 to 2.3) and positive margins (hazard ratio 1.837, 1.2 to 2.8) were independent predictors of worse overall survival. Conclusion: Oncological outcomes of MRF+ rectal cancer were not significantly influenced by the anatomical location of MRF involvement or MVR type.
- 3 July 2026
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 10 (4)
Open AccessOncological outcomes and treatment characteristics of patients with cT3-4 mesorectal fascia positive rectal cancer operated in 2016: Dutch nationwide cohort with standardized magnetic resonance imaging re-assessment
Background: Rectal cancer with mesorectal fascia involvement (MRF+) requires neoadjuvant downstaging and/or induction therapy, followed by (beyond) total mesorectal excision and/or multivisceral resection (MVR) depending on response. Decisions on the need for MVR and plane of dissection vary. This nationwide cross-sectional study aimed to evaluate treatment and oncological outcomes in MRF+ primary rectal cancer and the impact of MVR types. Methods: Using collaborative research, extensive clinical data on all rectal cancer resections in 2016 across 67 Dutch hospitals were retrospectively collected. Patients with cT3-4 MRF+ primary rectal cancer and standardized re-assessment of primary and restaging magnetic resonance imaging were selected. Patients were categorized by radiologically involved structures or organs and by MVR type. The primary outcome measures were microscopically positive margin (R1) resection rate, 4-year cumulative local recurrence, and 4-year overall survival. Results: Of 3178 patients registered, 571 cT3-4 MRF+ were selected resections, 125 of which were MVR. Tumours remained MRF+ on restaging magnetic resonance imaging in 76.4%. The overall R1 rate was 11.8% (9.7% in cT3/4a MRF+ and 17.9% in cT4b tumours). The R1 rate after MVR was 20.8%. Overall, the 4-year local recurrence rate was 15.1% and 4-year overall survival 67.5%. When comparing total mesorectal excision with MVR and/or beyond total mesorectal excision, the local recurrence rate was 12.7% versus 24.2% (P = 0.001), and overall survival 71.3% versus 53.7% (P < 0.001). Patients with radiological anterior involvement seemed to have a higher R1 rate compared with other locations. Anterior resections in both men and women appeared to be associated with relatively low local recurrence and high overall survival, whereas other resections resulted in numerically lower R1 rates, but worse long-term oncological outcomes. However, neither anatomical location of MRF+ and/or ingrowth nor MVR type was significantly associated with the primary outcomes. Pelvic sepsis (hazard ratio 1.533, 95% confidence interval 1.0 to 2.3) and positive margins (hazard ratio 1.837, 1.2 to 2.8) were independent predictors of worse overall survival. Conclusion: Oncological outcomes of MRF+ rectal cancer were not significantly influenced by the anatomical location of MRF involvement or MVR type.
- Open Access
- 23 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (6) , 109623
Salvageable locoregional recurrence and stoma rate after local excision of pT1-2 rectal cancer – A nationwide cross-sectional cohort study
- 23 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (6) , 109623
Open AccessSalvageable locoregional recurrence and stoma rate after local excision of pT1-2 rectal cancer – A nationwide cross-sectional cohort study
- Open Access
- 10 December 2024
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 24 (2) , 188-197.e1
Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands
- 10 December 2024
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 24 (2) , 188-197.e1
Open AccessIncidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands
- Open Access
- 8 August 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (11)
Esophagectomy after definitive chemoradiation in esophageal cancer: a safe therapeutic strategy
The standard treatment regimen for esophageal cancer is chemoradiation followed by esophagectomy. However, the use of neoadjuvant chemoradiotherapy damages the surrounding tissue, which potentially increases the risk of postoperative complications, including anastomotic leakage. The impact of definitive chemoradiotherapy (dCRT, 50.4 Gy radiotherapy) compared to the standard neoadjuvant scheme (nCRT, 41.4 Gy radiotherapy) prior to surgery on the incidence of anastomotic leakage remains poorly understood. To study this, all patients who received dCRT between 2011 and 2021 followed by esophagectomy were included. For each patient, two patients who received nCRT were selected as matched controls. Outcomes included postoperative anastomotic leakage, pulmonary and other complications, anastomotic stenosis, pulmonary and other postoperative complications (Clavien Dindo Classification ≥1), and overall survival. One hundred and eight patients were included with a median follow-up of 28 months. The time between neoadjuvant treatment and surgery was longer in the dCRT group compared to the nCRT group (65 vs. 48 days, P < 0.001). Postoperatively, significantly more patients in the dCRT group suffered from anastomotic leakage (11% vs. 1%, P = 0.04) and anastomotic stenosis (42% vs. 17%, P < 0.01). No differences were found for other complications or overall survival between both groups. In conclusion, preoperative dCRT is associated with a higher risk of anastomotic leakage and stenosis. These complications, however, can be treated effectively. Therefore, esophagectomy after dCRT is considered to be an appropriate treatment strategy in a selected patient group.
- 8 August 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (11)
Open AccessEsophagectomy after definitive chemoradiation in esophageal cancer: a safe therapeutic strategy
The standard treatment regimen for esophageal cancer is chemoradiation followed by esophagectomy. However, the use of neoadjuvant chemoradiotherapy damages the surrounding tissue, which potentially increases the risk of postoperative complications, including anastomotic leakage. The impact of definitive chemoradiotherapy (dCRT, 50.4 Gy radiotherapy) compared to the standard neoadjuvant scheme (nCRT, 41.4 Gy radiotherapy) prior to surgery on the incidence of anastomotic leakage remains poorly understood. To study this, all patients who received dCRT between 2011 and 2021 followed by esophagectomy were included. For each patient, two patients who received nCRT were selected as matched controls. Outcomes included postoperative anastomotic leakage, pulmonary and other complications, anastomotic stenosis, pulmonary and other postoperative complications (Clavien Dindo Classification ≥1), and overall survival. One hundred and eight patients were included with a median follow-up of 28 months. The time between neoadjuvant treatment and surgery was longer in the dCRT group compared to the nCRT group (65 vs. 48 days, P < 0.001). Postoperatively, significantly more patients in the dCRT group suffered from anastomotic leakage (11% vs. 1%, P = 0.04) and anastomotic stenosis (42% vs. 17%, P < 0.01). No differences were found for other complications or overall survival between both groups. In conclusion, preoperative dCRT is associated with a higher risk of anastomotic leakage and stenosis. These complications, however, can be treated effectively. Therefore, esophagectomy after dCRT is considered to be an appropriate treatment strategy in a selected patient group.
- Open Access
- 29 March 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108307
Prognostic significance of MRI-detected extramural venous invasion according to grade and response to neo-adjuvant treatment in locally advanced rectal cancer A national cohort study after radiologic training and reassessment
- 29 March 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108307
Open AccessPrognostic significance of MRI-detected extramural venous invasion according to grade and response to neo-adjuvant treatment in locally advanced rectal cancer A national cohort study after radiologic training and reassessment